首页> 外文期刊>Journal of Clinical Oncology >Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
【24h】

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

机译:用伊布勒替尼治疗慢性淋巴细胞白血病患者结果的预测:一种四因素预后模型的开发与验证

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for prognostication and risk-stratification are needed.
机译:目的:随机试验证实伊布替尼治疗慢性淋巴细胞白血病优于化学免疫治疗。伊布替尼无进展生存期(PFS)的持久性因患者亚组而异。需要用于预测和风险分层的临床工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号